Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population-based study of medicaid claims data
Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population-based study of medicaid claims data
复制标题
DOI:
10.4088/jcp.v69n0219
复制
发表时间:
2008-02-01
影响因子:
5.3
通讯作者:
Valuck, Robert J.
中科院分区:
文献类型:
--
作者:
Morrato, Elaine H.;Newcomer, John W.;Valuck, Robert J.
Objective: Increased risk of diabetes and dyslipidemia is associated with major mental illness and antipsychotic drug use. This study aimed to determine the prevalence of serum glucose and lipid monitoring in public mental health clients initiating second-generation antipsychotic (SGA) drugs.Method: This retrospective cohort study using Medicaid claims data from California, Oregon, Tennessee, and Utah evaluated 55,436 enrollees with a prescription claim for an SGA drug between January 1, 1998, and December 31, 2003. Serum glucose and lipid testing were identified using Current Procedural Terminology (CPT) procedure codes. Baseline was defined as 14 days before through 28 days after the date of the first SGA prescription. Multivariate logistic regression identified patient characteristics associated with testing. Generalized estimating equations evaluated changes associated with SGA drug initiation compared to background rates of testing.Results: On average, < 20% of individuals initiating SGA drug therapy received baseline glucose testing, and < 10% received baseline lipid testing. Baseline glucose and lipid testing increased modestly with SGA initiation (glucose: 7%-11% increase: lipids: 2%-3% increase; p